Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- 10 Dividend Picks For Your Portfolio: Chief Investors

MORE HEADLINES

» Markets | Economy | Companies

- Dubai Seeks Debt Delay, Stokes Default Fears

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Still Waiting On Witty

Published: Wednesday, 28 Oct 2009 | 11:15 AM ET

Text Size

By: Mike Huckman
CNBC Correspondent

GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu.

In fact, it is the only company that has products on both sides. GSK [GSK Loading... () ] makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago.

And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.

With all of the stories on shortages as well as the rumors and misinformation swirling about regarding vaccines, the flu and the medications to treat it, you’d think Witty would want to get out in front of it all. Wrong.

Witty has been running one of the world’s biggest drug companies for nearly a year-and-a-half now and he has yet to come on CNBC. In his early days, I was told he didn’t like doing TV, but to be patient. I was willing to give him a grace period. But then, I saw that he started doing TV “interviews” on GSK’s Web site. I’m almost certain it’s all softball stuff and that everything is pretty canned, coached and nearly scripted.

Health Care Bill With Public Option Hits Snags

Last week, Dr. Daniel Vasella of Novartis [NVS Loading... () ] gave us an interview devoted almost exclusively to the vaccine situation. And this Friday morning I’ll be talking to the CEO of the world’s biggest vaccine maker, Sanofi-Aventis’ Chris Viehbacher [SNY Loading... () ]. You can bet he will face some tough questions. In what could be a personal subplot to their starkly different media strategies, Viehbacher left GSK after his former colleague Witty beat him out for the top job. Viehbacher has been on CNBC several times. And Witty’s predecessor JP Garnier was a CNBC regular.

In fairness, Witty’s not alone. Jim Cornelius has been in charge of Bristol-Myers Squibb [BMY Loading... () ] for a few years and has yet to do a TV interview. He does a quarterly telephone conference call with reporters, but I boycott it because it does me absolutely no good as a TV reporter. I work in a visual medium. This isn’t about me being petulant. Sure, I want the get. If I didn’t have that competitive drive, I should be doing something else for a living. I just happen to think that the leaders of publicly-traded companies should be accessible and accountable and be expected to regularly answer questions from reporters in all mediums. That’s one of the reasons they’re paid the big bucks.